IMMUTEP LIMITED - AMER
2.0500
07-October-24 15:59:57
15 minutes delayed
Stocks
0.0000
0.00%
Today's range
2.0200 - 2.0900
ISIN
N/A
Source
NASDAQ
-
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
26 Apr 2023 08:00:00 By Nasdaq GlobeNewswire
-
17 Apr 2023 09:00:00 By Nasdaq GlobeNewswire
-
31 Mar 2023 08:00:00 By Nasdaq GlobeNewswire
-
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire
-
23 Mar 2023 08:00:00 By Nasdaq GlobeNewswire
-
14 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
06 Feb 2023 08:00:01 By Nasdaq GlobeNewswire
-
Immutep Quarterly Activities Report
30 Jan 2023 08:00:01 By Nasdaq GlobeNewswire
-
04 Jan 2023 08:00:01 By Nasdaq GlobeNewswire
-
23 Dec 2022 08:00:00 By Nasdaq GlobeNewswire
-
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
08 Dec 2022 08:00:01 By Nasdaq GlobeNewswire
-
06 Dec 2022 08:00:01 By Nasdaq GlobeNewswire
-
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
02 Dec 2022 08:00:00 By Nasdaq GlobeNewswire
-
Immutep Receives Australian R&D Tax Incentive
14 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
10 Nov 2022 09:00:02 By Nasdaq GlobeNewswire
-
09 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
04 Nov 2022 08:00:00 By Nasdaq GlobeNewswire